StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a report released on Tuesday morning. The firm issued a sell rating on the medical technology company’s stock. Other research analysts also recently issued reports about the company. Benchmark reissued a speculative buy rating and issued a $2.00 price objective on shares of […]